製品番号: HY-101795

Larixyl acetate

3 Cited Publications

カスタマーレビュー

Based on 3 publication(s) in Google Scholar

Larixyl acetate is a potent and selective TRPC6 inhibitor with IC₅₀ values of 0.58 μM and 6.83 μM against hTRPC6-YFP and hTRPC3-YFP, respectively. Larixyl acetate prevents HPV and is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.44%
CAS 番号: 4608-49-5
分子式: C₂₂H₃₆O₃
分子量:348.52

保管条件:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Larixyl acetate 構造式

CAS 番号: 4608-49-5

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
Publications (3)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

hTRPC6

0.58 μM (IC₅₀)

hTRPC3

6.83 μM (IC₅₀)

TRP Channel アイソフォーム固有の製品をすべて表示 :

Akt アイソフォーム固有の製品をすべて表示 :

Src アイソフォーム固有の製品をすべて表示 :

体外実験

Larixyl acetate (1-10 μM, 3 minutes) exerts its anti-inflammatory activity by inhibiting the phosphorylation of ERK1/2, AKT, and Src, suppressing fMLP-induced neutrophil migration, and inhibiting the interaction between βγ subunits and Src or PLCβ^[2].
Larixyl acetate (5 μM, 1 hour) effectively improves TBI-induced aortic endothelial dysfunction by inhibiting TRPC6 activity^[3].
Larixyl acetate (5 μM, 72 hours) significantly reduces the expression of ER stress genes and improves cell function in a cardiac hypertrophy cell model (H9c2 rat cardiomyocytes induced by Ang II)^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

Human neutrophils
Concentration:

1, 2, 5, 10 μM
Incubation Time:

3 min
Result:

Significantly inhibited fMLP-induced phosphorylation of ERK1/2, AKT, and Src.

Real Time qPCR^[5]

Cell Line:

H9c2 rat cardiomyocytes (cardiac hypertrophy model induced by Ang II (HY-13948))
Concentration:

5 μM
Incubation Time:

72 hours
Result:

Significantly reduced the mRNA expression of cardiac hypertrophy-related genes (e.g., ANP, BNP, Myh7).
Significantly reduced the expression of ER stress-related genes GRP78, pPERK, ATF4, and CHOP.

体内実験

Larixyl acetate (5 mg/kg, i.p., once dailly for 7 days) significantly improves aortic endothelial dysfunction in TBI mice by inhibiting TRPC6 activity, particularly enhancing acetylcholine-induced dilation^[3].
Larixyl acetate (5 mg/kg, i.p., once daily for 4 weeks) improves cardiac function in pressure overload-induced heart failure model by inhibiting TRPC6, reducing cardiac hypertrophy, fibrosis, and apoptosis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Closed-head mild traumatic brain injury (mTBI) model, C57BL/6, 129S, 129S-C57BL/6-F2 mice, TRPC6 knockout mice^[3]
Dosage:

5 mg/kg
Administration:

Intraperitoneal injection (i.p.), once daily for 7 days
Result:

Significantly improved aortic endothelial function 7 days after TBI.
Caused that acetylcholine (10 μM) induced dilation was significantly enhanced in Larixyl acetate-treated mice (In C57BL/6 mice, the Larixyl acetate group showed 96.9 %; in 129S-C57BL/6-F2 mice, the Larixyl acetate group showed 89.2 %).

Animal Model:

Transverse aortic constriction (Tac) model for pressure overload-induced heart failure in mice^[5]
Dosage:

5 mg/kg
Administration:

Intraperitoneal injection (i.p.), once daily for 4 weeks
Result:

Significantly reduced cardiac hypertrophy, left ventricular pressure, and improved cardiac function (FS and EF increased).
Improved TAC-induced cardiac fibrosis, cardiomyocyte apoptosis, and inhibited ER stress-related proteins (e.g., GRP78) expression.

化学情報

CAS 番号 4608-49-5
性状 Solid
分子量 348.52
分子式 C₂₂H₃₆O₃
Color White to off-white
SMILES

CC(CCC1)(C)[C@]([C@@]1(C)[C@H]2CC[C@](C)(O)C=C)([H])[C@@H](OC(C)=O)CC2=C
Structure Classification
- Others
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (3)

All

Sort by:

Journal Impact Factor

Int J Mol Sci

TRPC6 Deletion Enhances eNOS Expression and Reduces LPS-Induced Acute Lung Injury. [Abstract]

2023 Nov 25;24(23):16756. PMID: 38069081
Mol Med Rep

Larixyl acetate, a TRPC6 inhibitor, attenuates pressure overload‑induced heart failure in mice. [Abstract]

2024 Mar;29(3):49. PMID: 38275127
J Xenobiot

Phenotypic Subacute Toxicity Assessment of Intranasally Administered Larixyl Acetate: Implications for Potential Airway Applications. [Abstract]

2026 Jun 1;16(3):100. PMID: 42346422

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (286.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8693 mL

14.3464 mL

28.6928 mL

5 mM

0.5739 mL

2.8693 mL

5.7386 mL

10 mM

0.2869 mL

1.4346 mL

2.8693 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.17 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.17 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.17 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (281 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Urban N, et al. Identification and Validation of Larixyl Acetate as a Potent TRPC6 Inhibitor. Mol Pharmacol. 2016 Jan;89(1):197-213. [Content Brief]

[2]. Liao HR, et al. Larixol inhibits fMLP-induced superoxide anion production and chemotaxis by targeting the βγ subunit of Gi-protein of fMLP receptor in human neutrophils. Biochem Pharmacol. 2022 Jul;201:115091. [Content Brief]

[3]. Chen X, et al. The TRPC6 inhibitor, larixyl acetate, is effective in protecting against traumatic brain injury-induced systemic endothelial dysfunction. J Neuroinflammation. 2019 Jan 31;16(1):21. [Content Brief]

[4]. Wang J, et al. The analgesic action of larixyl acetate, a potent TRPC6 inhibitor, in rat neuropathic pain model induced by spared nerve injury. J Neuroinflammation. 2020 Apr 16;17(1):118. [Content Brief]

[5]. Jia M, et al. Larixyl acetate, a TRPC6 inhibitor, attenuates pressure overload‑induced heart failure in mice. Mol Med Rep. 2024 Mar;29(3):49. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8693 mL	14.3464 mL	28.6928 mL	71.7319 mL
	5 mM	0.5739 mL	2.8693 mL	5.7386 mL	14.3464 mL
	10 mM	0.2869 mL	1.4346 mL	2.8693 mL	7.1732 mL
	15 mM	0.1913 mL	0.9564 mL	1.9129 mL	4.7821 mL
	20 mM	0.1435 mL	0.7173 mL	1.4346 mL	3.5866 mL
	25 mM	0.1148 mL	0.5739 mL	1.1477 mL	2.8693 mL
	30 mM	0.0956 mL	0.4782 mL	0.9564 mL	2.3911 mL
	40 mM	0.0717 mL	0.3587 mL	0.7173 mL	1.7933 mL
	50 mM	0.0574 mL	0.2869 mL	0.5739 mL	1.4346 mL
	60 mM	0.0478 mL	0.2391 mL	0.4782 mL	1.1955 mL
	80 mM	0.0359 mL	0.1793 mL	0.3587 mL	0.8966 mL
	100 mM	0.0287 mL	0.1435 mL	0.2869 mL	0.7173 mL

Keywords

Larixyl acetate

3 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Larixyl acetate

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Endoplasmic Reticulum Stress Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Mechanoreceptors Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Ion Channel Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Posttranslational Modification Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Antiviral Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

MedChemExpress（MCE）の使用を引用している文献 Larixyl acetate

TRP Channel アイソフォーム固有の製品をすべて表示

Akt アイソフォーム固有の製品をすべて表示

Src アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (3)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Larixyl acetate 関連分類

HY-101795 関連分類